Yukihiro Hasegawa
Aomori, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Biweekly carboplatin plus nab-paclitaxel with concurrent radiotherapy followed by durvalumab consolidation for unresectable locally advanced non-small cell lung cancer: a real-world retrospective cohort study.
Journal: Translational lung cancer research
Published: February 09, 2026
Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis.
Journal: JTO clinical and research reports
Published: June 16, 2025
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).
Journal: Therapeutic advances in medical oncology
Published: February 07, 2025
Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 10, 2024
Feasibility and safety of platinum-doublet therapy in patients with small-cell lung cancer in the third-line setting: A multi-institutional retrospective study.
Journal: Oncology letters
Published: June 16, 2022
Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).
Journal: Thoracic cancer
Published: April 13, 2021
The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study.
Journal: SAGE open medicine
Published: December 21, 2020
A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
Journal: Clinical lung cancer
Published: July 07, 2020
Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
Journal: Medical oncology (Northwood, London, England)
Published: February 25, 2019
The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations.
Journal: Molecular and clinical oncology
Published: September 19, 2018
Integrated treatment for autonomic paraneoplastic syndrome improves performance status in a patient with small lung cell carcinoma: a case report.
Journal: BMC neurology
Published: March 05, 2018
Last Updated: 09/26/2026